Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDMP/Rituximab Debulking Prior to Venetoclax in Relapsed/Refractory CLL/SLL
NCT04981912Phase 1Completed
- Sponsor
- University of California, San Diego
- Start
- Sep 2021
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of methylprednisolone and rituximab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by University of California, San Diego. Primary endpoint: Percentage of Patients That Have a Decrease in Tumor Burden From Medium or High to Low at 56 days. Started Sep 2021; status: completed.
02
Drugs
methylprednisolonerituximab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04981912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04981912.